Precision BioSciences receives $9.75M cash + $3.25M Imugene shares from convertible note maturity

PRECISION BIOSCIENCES INC

Convertible note from August 2023 azer-cel deal with Imugene matured; Precision receives $9.75M cash and $3.25M in Imugene ordinary shares.
Cash injection extends expected runway into second half of 2026; Q2 2024 cash balance was ~$123.6M before this receipt.
Company on track to file applications for PBGENE-HBV (chronic hepatitis B) with multiple global regulators later in 2024.
Precision expects to generate Phase 1 clinical data across multiple in vivo gene editing programs starting first half of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.